Skip to main content
Lasa Supergenerics Limited logo

Lasa Supergenerics Limited — Investor Relations & Filings

Ticker · LASA ISIN · INE670X01014 LEI · 984500B9EA5EC3R2F726 BSE.NS Manufacturing
Open in API
Filings indexed 463 across all filing types
Latest filing 2022-03-09 Legal Proceedings Report
Country IN India
Listing BSE.NS LASA

About Lasa Supergenerics Limited

https://lasalabs.com/

Lasa Supergenerics Limited is a vertically integrated manufacturer specializing in Active Pharmaceutical Ingredients (APIs) for both veterinary and human health applications. The company focuses on the research, development, and production of high-quality chemical intermediates and APIs. Its core product portfolio includes a significant range of anthelmintics, such as Albendazole, Fenbendazole, and Ricobendazole, alongside other specialized therapeutic categories. Utilizing advanced manufacturing facilities and a dedicated research and development wing, the organization emphasizes cost-effective production processes and stringent quality control standards. Lasa Supergenerics Limited serves a global clientele, providing essential components for pharmaceutical formulations and animal health products through its expertise in complex chemical synthesis and large-scale manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Press Release
Legal Proceedings Report Classification · 100% confidence The document is a press release announcing that Lasa Supergenerics Limited has filed a legal suit for permanent injunction against a competitor regarding patent infringement. It details the nature of the suit, the patent involved, and the compensation sought. There is no financial data, no report attached or referenced as being published, and no mention of financial results or management changes. The content focuses on legal proceedings related to intellectual property and business interference. Therefore, this document fits the category of Legal Proceedings Report (LTR).
2022-03-09 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2022-02-15 English
Financial Result Updates
Regulatory Filings
2022-02-08 English
Outcome of Board Meeting
Earnings Release Classification · 95% confidence The document is a formal communication addressed to stock exchanges reporting the outcome of a board meeting held on February 7, 2022. It states that the Board of Directors approved the unaudited financial results for the quarter and nine months ended December 31, 2021, and the limited review report from the statutory auditor for the same period. The document is short (1731 characters) and serves as an announcement of the approval of financial results rather than containing the full financial statements or detailed analysis. It does not include the actual financial data but informs about the approval and availability of the results elsewhere. Therefore, this document is best classified as an Earnings Release (ER), which is the initial announcement of quarterly/periodical financial results (key highlights only). 9M 2022
2022-02-07 English
Board Meeting — Financial Results
Board/Management Information Classification · 95% confidence The document is a notice titled 'Board Meeting Intimation' addressed to stock exchanges, informing about a scheduled board meeting to consider and approve un-audited financial results for the quarter ended December 31, 2021. It references regulatory compliance under SEBI regulations and mentions the trading window closure. The document is short (1877 characters) and serves as an announcement of an upcoming board meeting and financial results approval, not the financial report itself. Therefore, it is an announcement related to board/management activities rather than the actual report or detailed financial data. The appropriate classification is 'MANG' for Board/Management Information.
2022-01-29 English
Corporate Insolvency Resolution Process
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) disclosing the filing of an application before the National Company Law Tribunal under Section 7 of the Insolvency and Bankruptcy Code, 2016. It informs about a petition filed by a financial creditor seeking initiation of Corporate Insolvency Resolution Process against the company. The document is a regulatory disclosure under SEBI Listing Regulations, specifically Regulation 30, which mandates timely disclosure of material events. The document does not contain financial statements, audit information, or detailed reports but is an announcement of a legal/regulatory event affecting the company. It is not a full report, earnings release, or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance disclosures that do not fit other specific categories. The document length is short (2458 characters), and it is not an announcement of a report publication but a direct regulatory disclosure. Confidence is high due to clear regulatory context and content.
2022-01-12 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.